Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of IV and SC Dasiglucagon in Healthy Subjects
NCT03735225Phase 1Completed
- Sponsor
- Zealand Pharma
- Start
- Nov 2018
- Primary completion
- Jun 2019
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of dasiglucagon in hypoglycemia (3 arms), sponsored by Zealand Pharma. Primary endpoint: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 at Day 28. Started Nov 2018; status: completed.
02
Drugs
dasiglucagon
03
Conditions
hypoglycemia
Beyond the preview
Go deeper on NCT03735225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03735225.